Page 54 - Read Online

Page 14 of 17 Balakrishnan et al. J Cancer Metastasis Treat 2022;8:27 https://dx.doi.org/10.20517/2394-4722.2022.33

26. Haas L, Obenauf AC. Allies or enemies-the multifaceted role of myeloid cells in the tumor microenvironment. Front Immunol
2019;10:2746. DOI PubMed PMC
27. Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting
cells critical for T cell immunity. Cancer Cell 2014;26:638-52. DOI
+
28. Liu J, Rozeman EA, O’Donnell JS, et al. Batf3 DCs and type I IFN are critical for the efficacy of neoadjuvant cancer
immunotherapy. Oncoimmunology 2019;8:e1546068. DOI PubMed PMC
29. Wculek SK, Amores-Iniesta J, Conde-Garrosa R, Khouili SC, Melero I, Sancho D. Effective cancer immunotherapy by natural mouse
conventional type-1 dendritic cells bearing dead tumor antigen. J Immunother Cancer 2019;7:100. DOI PubMed PMC
30. Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun 2019;10:5408. DOI
PubMed PMC
31. Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng
2018;2:341-6. DOI PubMed PMC
32. Noubade R, Majri-Morrison S, Tarbell KV. Beyond cDC1: emerging roles of DC crosstalk in cancer immunity. Front Immunol
2019;10:1014. DOI PubMed PMC
+ +
33. Brewitz A, Eickhoff S, Dähling S, et al. CD8 T Cells orchestrate pDC-XCR1 dendritic cell spatial and functional cooperativity to
optimize priming. Immunity 2017;46:205-19. DOI PubMed PMC
34. Conrad C, Gregorio J, Wang YH, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS
costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012;72:5240-9. DOI PubMed PMC
35. Aspord C, Leccia MT, Charles J, Plumas J. Melanoma hijacks plasmacytoid dendritic cells to promote its own progression.
Oncoimmunology 2014;3:e27402. DOI PubMed PMC
36. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and
adaptive immunity. Cancer Res 2011;71:2488-96. DOI PubMed PMC
37. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and
chemotherapy-induced immunogenic cell death. Oncoimmunology 2014;3:e28518. DOI PubMed PMC
38. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity 2013;39:211-27. DOI PubMed
39. Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege
and disease progression through PD-L1. J Exp Med 2009;206:1327-37. DOI PubMed PMC
40. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
DOI PubMed
41. Grazioli P, Felli MP, Screpanti I, Campese AF. The mazy case of Notch and immunoregulatory cells. J Leukoc Biol 2017;102:361-8.
DOI PubMed
42. Cheng P, Kumar V, Liu H, et al. Effects of notch signaling on regulation of myeloid cell differentiation in cancer. Cancer Res
2014;74:141-52. DOI PubMed PMC
43. Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloid-derived suppressor cells as functional antigen-
presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 2012;131:741-51. DOI PubMed
44. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-
associated myeloid-derived suppressor cells. Cancer Res 2007;67:11021-8. DOI PubMed
45. Wu L, Zhang XH. Tumor-associated neutrophils and macrophages-heterogenous but not chaotic. Front Immunol 2020;11:553967.
DOI
46. Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol 2018;8:49. DOI PubMed PMC
47. Saleem SJ, Conrad DH. Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC
expansion. Int Immunopharmacol 2011;11:808-15. DOI PubMed PMC
48. Wang SH, Lu QY, Guo YH, Song YY, Liu PJ, Wang YC. The blockage of Notch signalling promoted the generation of
polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. Eur J Cancer 2016;68:90-105. DOI PubMed
49. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-8. DOI
PubMed PMC
50. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of
radiotherapy in prostate cancer. Cancer Res 2013;73:2782-94. DOI PubMed PMC
51. Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma.
Nature 2014;507:109-13. DOI PubMed
52. Zhou SL, Zhou ZJ, Hu ZQ, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of
hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 2016;150:1646-1658.e17. DOI PubMed
53. Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014;344:921-5.
DOI PubMed PMC
54. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015;27:462-72. DOI PubMed PMC
55. Cassetta L, Kitamura T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune
checkpoint inhibitors. Front Cell Dev Biol 2018;6:38. DOI PubMed PMC
56. Badawi MA, Abouelfadl DM, El-Sharkawy SL, El-Aal WE, Abbas NF. Tumor-associated macrophage (TAM) and angiogenesis in
human colon carcinoma. Open Access Maced J Med Sci 2015;3:209-14. DOI PubMed PMC